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OBJECTIVES: Colorectal cancer poses a significant disease burden inWest Virginia.
Hospitalization followed by surgical resection is the standard curative treatment.
Emergency admissions account for more than 25% of colorectal cancer hospital-
izations nationwide. The aim of this study is to compare characteristics of West
Virginia residents admitted emergently, urgently or electively to West Virginia
hospitals between 2003-2007. Another aimwas to explain the association between
admission type and in-hospital deaths.METHODS: Data from the Healthcare Cost
and Utilization Project (HCUP), State Inpatient Database were investigated. De-
scriptive statistics for admission type, comorbidities, in-hospital death, age and
sex were tabulated; chi-square analyses helped explain differences in characteris-
tics between admission types. Logistic regression was employed to explain differ-
ences in in-hospital deaths between emergency, urgent and elective admissions.
RESULTS: There were 9380 admissions with a primary or secondary diagnosis of
CRC of which 33.1% were emergency admissions, 24.4% urgent and 42.1% elective.
Of the in-hospital deaths more than half (50.5%) the cases were admitted emer-
gently compared to electively (23.1%). Among emergency and urgent admissions
the most common comorbid conditions were diabetes (17.1%), followed by fluid
disorders (6.9%) and hypertension (5.0%). Among elective admissions diabetes
(19.9%) was followed by COPD (4.3%) and hypertension (3.5%). Logistic regression
showed that the odds of in-hospital death were 3.03 times higher for emergency
admission compared to elective after controlling for age, sex, number of comor-
bidities, diagnosis type and payer. CONCLUSIONS: Patients admitted emergently
are more likely to die in-hospital compared to those admitted electively. The large
percentage of patients admitted emergently indicates advanced disease and pos-
sibly failure of timely screening. Comorbid conditions differed by admission type
and need further investigation. Diabetes was the most common comorbid condi-
tion overall and further investigation in diabetics is needed to check screening
behavior and access to screening centers.
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OBJECTIVES: HTA agencies have different requirements and preferences in terms
of both themodels they receive and the clinical evidence that submission are based
on. Our aimwas to understand what could be learned about the preferences of the
PBAC in Australia and NICE and the SMC in the UK specific to oncology from five
selected case studies. METHODS: Five high-profile cancer drugs, namely Avastin
(bevacizumab), Erbitux (cetuximab), Sprycel (dasatinib), Tykerb/Tyverb (lapatinib)
and Tarceva (erlotinib) were selected as our research sample. All assessment guid-
ance related to the five drugs by NICE, the PBAC and the SMC were reviewed to
examine the rationale behind positive or negative recommendations. Based on the
review, we analysed the agencies’ preferences for oncology HTA submissions.
RESULTS: Avastin has been one of the most rejected drugs among the three agen-
cies, with the exception of PBAC’s recommendation of listing for 1st linemetastatic
colorectal cancer treatment on the condition of a patient access scheme. The in-
crease to the overall drug cost by including Avastin in the treatment regimen has
been the main concern with other negative factors including the inappropriate
choice of comparators.Tykerb received negative recommendations from both
PBAC and SMC for breast cancer due to concerns over small trial population size,
robustness of efficacy evidence as well as high ICER. Between the 5 drugs, 21 HTA
reviews took place, resulting in 11 positive recommendations, 10 rejections and 1
deferred decision for further price negotiation. Out of the positive recommenda-
tions, 4 were based on risk sharing arrangements. CONCLUSIONS: HTA agencies
responddifferently to submissions based on the same clinical dossier. Understand-
ing in detail what the evidence preferences are of the individual agencies is crucial
of the probability of reimbursement is to bemaximised. This understanding should
be fed into clinical development and supplementary evidence plans.
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OBJECTIVES: Considering human factors in new technology is essential to ensure
its acceptance, particularly in underserved communities. This study assessed the
usability of the original (Flash) and new (HTML) versions of a self-administered
familial cancer risk assessment tool- the Jameslink. METHODS: The study was a
randomized, hybrid experimental design involving in-person usability testing of
predominantly lower-income, African American individuals 18 years or older.
Flash and HTML versions of the Jameslink were compared for the outcomes of
grade (A-F), personal relevance, ease of use, and time to complete. RESULTS:Most
of the respondents were female (71.2%) and African American (93.3%), with amean
age of 43.41 (13.61) years. Many had annual income $25,000 (33.9%) and educa-
tion of high school degree or less (28.8%). Principal components analysis with Va-
rimax rotation showed one factor solutions with eigen values1 - Scale 1: ease of
use of the program (understandability, organization, going through pages, and
printing Jameslink) and Scale 2: relevance of Jameslink (important, interesting,
makes sense, and self-relevant); both scales had excellent internal consistency
(Cronbach’s alphas0.822 and 0.866 respectively). Independent sample t-tests and
chi-square analysis revealed that participants felt Flash providedmore personally-
relevant information and was easier to use compared to HTML. Further, they gave
a better grade to Flash, and Flash took less time to complete (all p’s0.05, adjusted).
Grounded theory analysis found that Flash versionwas clear, concise, informative,
but the layout could be improved whereas HTML version was confusing, stressful,
complicated, and involved toomuch typing. CONCLUSIONS:Althoughwemade an
effort to integrate our familial cancer risk assessment tool in the HTML platform of
a larger, personalized health assessment tool from the university, we found that
our original Flash version was better accepted in this underserved population.
Consideration of human factors is essential to encourage personalized health as-
sessment and understanding of risk status.
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OBJECTIVES: This study seeks to compare the actual cost (minus administration
costs) of bortezomibmonotherapy treatment versus lenalidomide/dexamethasone
therapy in second-linemultiplemyeloma (MM) in the United States and the United
Kingdom. It also reviews decisions on second-line MMmade by health technology
assessment (HTA) agencies.METHODS: The IHS OncoInsight Market Access Data-
base was reviewed to find the ex-manufacturing package price and price per mg of
each drug. The average cost per treatment was calculated by multiplying the fac-
tory price per mg by the average total mg per treatment, calculated using the
official dosage and duration of use from the drugs’ labels. All prices were from H1
2010. Additionally, HTA decisions on the drugs were identified. RESULTS: The total
average treatment cost for the lenalidomide/dexamethasone treatment was
$101,052.75 in the United States and £58,926.78 in the United Kingdom.The total
average treatment costs of bortezomibmonotherapy were $17,045.53 and £9,708.2.
Using the highest number of doses documented in the APEX study, the totals come
to $34,091.06 and £19,416.4.The U.K. National Institute for Health and Clinical Ex-
cellence (NICE) has reviewed both therapies in previously treated MM. In October
2007, NICE recommended bortezomib monotherapy for second-line MM. In June
2009, NICE recommended lenalidomide plus dexamethasone in third-line MM.
Both recommendations were subject to a patient access scheme. CONCLUSIONS:
The overall cost of bortezomib monotherapy was found to be potentially lower
than Revlimid plus dexamethasone in second-line MM. Even when taking into
account a higher dose regimen for bortezomib monotherapy, its cost is still signif-
icantly lower than the lenalidomide combination therapy. However, the mode of
administration—injectable versus oral—is likely to be taken into account by pay-
ors. These findings are consistent with NICE, which recommends bortezomib
monotherapy for second-line treatment and lenalidomide combination only for
third-line treatment.
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OBJECTIVES: The health status of the population of Central-Eastern Europe (CEE) is
worse than that of Western Europe, this is especially true for malignant diseases.
Furthermore, these countries have more limited health care resources; therefore,
transparent decision criteria, including the assessment of cost-effectiveness in
formal health technology assessments (HTA), are an absolute necessity. Unfortu-
nately, the number of trained health economists and prospective health economic
trials and the public budget for HTA are not comparable to the major markets of
innovative health technologies, such as those of the United Kingdom. Transferabil-
ity of good quality HTA reports, especially those prepared by the National Institute
for Health and Clinical Excellence (NICE), could be highly beneficial to prevent the
duplication of efforts and to save resources for local health technology
assessments. METHODS: We scrutinized the transferability of 68 published NICE
appraisals of innovative oncological drugs to CEE countries. The most critical fac-
tors influencing the transferability of NICE appraisals were selected based upon
differences in measures between UK and CEE countries RESULTS: In general, we
can conclude that HTA recommendations by the NICE are not transferable. Certain
elements of HTA reports are transferable, but adjustment to local data is absolutely
necessary. If the NICE recommendation is positive, the conclusion can be still
negative in CEE countries; this is primarily due to relative price differences and the
significance of local budget impacts. If the NICE recommendation is negative, the
innovative health technology can be still cost-effective in Central-Eastern Europe
due to the worse health status of the population and the greater potential health
impact on the targeted population. CONCLUSIONS: Decision-makers in CEE coun-
tries cannot make excuses; they must improve the appropriateness of reimburse-
ment decisions to increase the allocative efficiency of health care financing, but
copyingNICE recommendationswithout local adjustmentmay domore harm than
good.
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